At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
In Brief
A Phase 3 clinical trial evaluating Hypoglycemic Agents, Standard glycemia control, and 5 other interventions for Diabetic Retinopathy. Completed, enrolled 3,472 participants across 7 sites in 2 countries.
Detailed Summary
Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various treatments on cardiovascular disease in people with diabetes. This current study will examine the effects of the ACCORD treatments on the progression of DR in people participating in the ACCORD study.
Study Details
Timeline
Interventions
Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
A strategy of glycemia drugs for HbA1c 7% - 7.9%
A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
A strategy of BP drugs for SBP less than 140 mm Hg
Blinded fenofibrate
Simvastatin 20-40 mg/d
Placebo